CVS Pharmacy reported on Friday the launch of the Hepatitis A vaccine programme in Kentucky following a rise in confirmed cases of the virus across the state.
According to the Kentucky Department for Public Health, more than 300 Hepatitis A cases have reportedly been confirmed across the state since 2017. Most recently, cases have been confirmed in Ashland, Berea and Louisville.
All 79 CVS Pharmacy locations in Kentucky, including the nine CVS Pharmacy in Target locations, have the Hepatitis A vaccine available for people who have not yet been vaccinated. The stores located in Ironton, OH and Kenova, WV as well as the three MinuteClinic locations in Kentucky have the vaccine in stock.
Consumers can visit CVS.com or use the CVS Pharmacy app to locate a nearby CVS Pharmacy and to schedule a Hepatitis A vaccination appointment. CVS pharmacists can provide the Hepatitis A vaccine to people ages 18 and up. It is administered in one primary dose and a second booster dose. Vaccine supplies will be replenished at the locations as needed. Patients should check with their insurance plans for coverage details prior to their CVS Pharmacy visit.
CVS Pharmacy is America's leading retail pharmacy with over 9,800 locations and the retail division of CVS Health (NYSE:CVS).
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine